FOSUN PHARMA (02196) is experiencing a significant surge in its stock price, soaring 5.11% during Friday's trading session. The pharmaceutical giant's shares are rallying on the back of impressive financial results for the first nine months of 2025 and positive developments in its innovative product pipeline.

Despite a 4.91% year-on-year decrease in revenue to RMB29.39 billion, FOSUN PHARMA reported a substantial 25.5% increase in net profit attributable to shareholders, reaching RMB2.52 billion. The company's basic earnings per share stood at RMB0.95. This robust profit growth was primarily driven by gains from the divestment of remaining equity in United Family Healthcare and other non-core assets, demonstrating the company's strategic focus on core operations.

Investors are also optimistic about FOSUN PHARMA's advancing innovative product pipeline. In September 2025, the company's novel small-molecule CDK4/6 inhibitor FCN-437c received approval for an additional indication in China. Furthermore, HLX14, a denosumab biosimilar, secured approvals for launch in both the U.S. and EU markets. The company's FKC889 (brexucabtagene autoleucel injection) has also made progress, with its domestic marketing application accepted by China's NMPA. Analysts from Guotai Junan Securities believe that the sequential launch of these innovative drugs will drive revenue recovery, contributing to the positive market sentiment surrounding FOSUN PHARMA.